Search

Your search keyword '"Tabata, Ken-ichi"' showing total 349 results
Start Over Author "Tabata, Ken-ichi"
349 results on '"Tabata, Ken-ichi"'

3. Predictive Value of the Prostate-Specific Antigen Doubling Time for the Effectiveness of Metastasis-Directed Radiotherapy in Patients with Oligometastases after Radical Treatment for Non-metastatic Prostate Cancer: A Single Institution Retrospective Study

Author

Koguchi, Dai, primary, Tabata, Ken-ichi, additional, Hirano, Shuhei, additional, Shimura, Soichiro, additional, Satoh, Takefumi, additional, Ikeda, Masaomi, additional, Matsumoto, Kazumasa, additional, Niibe, Yuzuru, additional, and Iwamura, Masatsugu, additional

Published
2024
Full Text
View/download PDF

4. Real-world data on the comprehensive genetic profiling test for Japanese patients with metastatic castration-resistant prostate cancer

Author

Koguchi, Dai, primary, Tsumura, Hideyasu, additional, Tabata, Ken-ichi, additional, Shimura, Soichiro, additional, Satoh, Takefumi, additional, Ikeda, Masaomi, additional, Watanabe, Akinori, additional, Yoshida, Tsutomu, additional, Sasaki, Jiichiro, additional, Matsumoto, Kazumasa, additional, and Iwamura, Masatsugu, additional

Published
2024
Full Text
View/download PDF

6. Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial

Author

Uemura, Hiroji, Matsushima, Hisashi, Kobayashi, Kazuki, Mizusawa, Hiroya, Nishimatsu, Hiroaki, Fizazi, Karim, Smith, Matthew, Shore, Neal, Tammela, Teuvo, Tabata, Ken-ichi, Matsubara, Nobuaki, Iinuma, Masahiro, Uemura, Hirotsugu, Oya, Mototsugu, Momma, Tetsuo, Kawakita, Mutsushi, Fukasawa, Satoshi, Kobayashi, Tadahiro, Kuss, Iris, Le Berre, Marie-Aude, Snapir, Amir, Sarapohja, Toni, and Suzuki, Kazuhiro

Published
2021
Full Text
View/download PDF

11. Comparison of Sequential Treatment With Androgen Receptor-Targeted Agent Followed by Another Androgen Receptor-Targeted Agent Versus Androgen Receptor-Targeted Agent Followed by Docetaxel in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer

Author

Matsubara, Nobuaki, Yamada, Yoko, Tabata, Ken-ichi, Satoh, Takefumi, Kamiya, Naoto, Suzuki, Hiroyoshi, Kawahara, Takashi, Uemura, Hiroji, Yano, Akihiro, Kawakami, Satoru, Otsuka, Masafumi, and Fukasawa, Satoshi

Published
2017
Full Text
View/download PDF

14. Data from Functional Analysis of Secreted Caveolin-1 in Mouse Models of Prostate Cancer Progression

Author

Watanabe, Masami, primary, Yang, Guang, primary, Cao, Guangwen, primary, Tahir, Salahaldin A., primary, Naruishi, Koji, primary, Tabata, Ken-ichi, primary, Fattah, Elmoataz Abdel, primary, Rajagopalan, Kartik, primary, Timme, Terry L., primary, Park, Sanghee, primary, Kurosaka, Shinji, primary, Edamura, Kohei, primary, Tanimoto, Ryuta, primary, Demayo, Francesco J., primary, Goltsov, Alexei A., primary, and Thompson, Timothy C., primary

Published
2023
Full Text
View/download PDF

16. Supplementary Data from Functional Analysis of Secreted Caveolin-1 in Mouse Models of Prostate Cancer Progression

Author

Watanabe, Masami, primary, Yang, Guang, primary, Cao, Guangwen, primary, Tahir, Salahaldin A., primary, Naruishi, Koji, primary, Tabata, Ken-ichi, primary, Fattah, Elmoataz Abdel, primary, Rajagopalan, Kartik, primary, Timme, Terry L., primary, Park, Sanghee, primary, Kurosaka, Shinji, primary, Edamura, Kohei, primary, Tanimoto, Ryuta, primary, Demayo, Francesco J., primary, Goltsov, Alexei A., primary, and Thompson, Timothy C., primary

Published
2023
Full Text
View/download PDF

19. Management of patients with advanced prostate cancer in Japan: ‘real-world’ consideration of the results from the Advanced Prostate Cancer Consensus Conference

Author

Fujita, Kazutoshi, primary, Suzuki, Hiroyoshi, additional, Hinata, Nobuyuki, additional, Miura, Yuji, additional, Edamura, Kohei, additional, Tabata, Ken-Ichi, additional, Arai, Gaku, additional, Matsubara, Nobuaki, additional, Yasumizu, Yota, additional, Kosaka, Takeo, additional, Oya, Mototsugu, additional, and Sugimoto, Mikio, additional

Published
2022
Full Text
View/download PDF

21. Local and Distant Effects of Caveolin-1 on Prostate Cancer Progression

Author

Thompson, T. C., Tahir, S. A., Li, L., Watanabe, M., Naruishi, K., Yang, G., Tabata, Ken-ichi, Kurosaka, S., Edamura, K., Tanimoto, R., Corn, P., Kadmon, D., Logothetis, C. J., Troncoso, P., Ren, C., Goltsov, A., Park, S., Mercier, Isabelle, editor, Jasmin, Jean-François, editor, and Lisanti, Michael P., editor

Published
2012
Full Text
View/download PDF

24. PD22-05 COMPARISON OF LOW-DOSE-RATE BRACHYTHERAPY VERSUS RADICAL PROSTATECTOMY IN PATIENTS WITH INTERMEDIATE-RISK PROSTATE CANCER: A PROPENSITY-MATCHED MULTI-INSTITUTIONAL STUDY

Author

Tsumura, Hideyasu, primary, Tanaka, Nobumichi, additional, Oguchi, Tomohiko, additional, Owari, Takuya, additional, Nakai, Yasushi, additional, Asakawa, Isao, additional, Iijima, Kazuyoshi, additional, Kato, Haruaki, additional, Hashida, Iwao, additional, Tabata, Ken-ichi, additional, Satoh, Takefumi, additional, and Ishiyama, Hiromichi, additional

Published
2022
Full Text
View/download PDF

26. Additional file 1 of Direct comparison of low-dose-rate brachytherapy versus radical prostatectomy using the surgical definition of biochemical recurrence for patients with intermediate-risk prostate cancer

Author

Tsumura, Hideyasu, Tanaka, Nobumichi, Oguchi, Tomohiko, Owari, Takuya, Nakai, Yasushi, Asakawa, Isao, Iijima, Kazuyoshi, Kato, Haruaki, Hashida, Iwao, Tabata, Ken-ichi, Satoh, Takefumi, and Ishiyama, Hiromichi

Subjects
food and beverages
Abstract

Additional file 1. Table S1. Causes of death in patients treated with SEED-BT and RP.

Published
2022
Full Text
View/download PDF

27. Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.

Author

Ishii, Hidetoshi, Kokubun, Hideya, Tabata, Ken-ichi, and Kanai, Akifumi

Subjects
THERAPEUTIC use of transdermal medication, CANCER patient psychology, FENTANYL, PERSPIRATION, PAIN management
Abstract

(Case 1) A 45-year-old male was diagnosed with prostate cancer. Treatment was administered using bicalutamide and leuprorelin acetate, while a transdermal fentanyl (TDF) was applied for pain relief. However, TDF continued to peel off owing to excessive sweating, even when reinforced by a protective layer. As such, TDF was discontinued and pain control was initiated using other medicines. Sweating occurred irregularly because of hot flashes, approximately four to five times per day. (Case 2) A 37-year-old male was diagnosed with a malignant thymoma and sacral metastasis. For analgesic control, etodolac tablets, carbamazepine tablets, and TDF were administered. Subsequently, the dose of the TDF was gradually increased, but the analgesic effect was low; thus, fentanyl blood concentration was measured. The measurements showed that even higher TDF doses did not increase fentanyl blood levels. During this period, full body sweating began to occur to a large extent due to unknown causes, and it was thought that the absorption of fentanyl decreased. When using a TDF, it is necessary to monitor patients for any sweating during treatment, while also considering changes in medication in some cases. This should promote the maintenance and improvement of the quality of life of the affected patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

28. Comparative Effectiveness Of Low-Dose-Rate Brachytherapy Alone Or Combined With External-Beam Radiotherapy In Intermediate-Risk Prostate Cancer: A Propensity-Matched Multi-Institutional Study

Author

Tsumura, Hideyasu, primary, Tanaka, Nobumichi, additional, Oguchi, Tomohiko, additional, Owari, Takuya, additional, Nakai, Yasushi, additional, Asakawa, Isao, additional, Iijima, Kazuyoshi, additional, Kato, Haruaki, additional, Hashida, Iwao, additional, Tabata, Ken-ichi, additional, Satoh, Takefumi, additional, and Ishiyama, Hiromichi, additional

Published
2022
Full Text
View/download PDF

29. Direct Comparison of Low-Dose-Rate Brachytherapy Versus Radical Prostatectomy Using the Surgical Definition of Biochemical Recurrence for Patients with Intermediate-Risk Prostate Cancer

Author

Tsumura, Hideyasu, primary, Tanaka, Nobumichi, additional, Oguchi, Tomohiko, additional, Owari, Takuya, additional, Nakai, Yasushi, additional, Asakawa, Isao, additional, Iijima, Kazuyoshi, additional, Kato, Haruaki, additional, Hashida, Iwao, additional, Tabata, Ken-ichi, additional, Satoh, Takefumi, additional, and Ishiyama, Hiromichi, additional

Published
2022
Full Text
View/download PDF

35. Cancer‐specific and net overall survival in older patients with de novo metastatic prostate cancer initially treated with androgen deprivation therapy.

Author

Narita, Shintaro, Terada, Naoki, Nomura, Kyoko, Sakamoto, Shinichi, Hatakeyama, Shingo, Kato, Takuma, Matsui, Yoshiyuki, Inokuchi, Junichi, Yokomizo, Akira, Tabata, Ken‐ichi, Shiota, Masaki, Kimura, Takahiro, Kojima, Takahiro, Inoue, Takahiro, Mizowaki, Takashi, Sugimoto, Mikio, Kitamura, Hiroshi, Kamoto, Toshiyuki, Nishiyama, Hiroyuki, and Habuchi, Tomonori

Subjects
ANDROGEN deprivation therapy, PROSTATE cancer, OLDER patients, OVERALL survival, METASTASIS, PROSTATE cancer patients
Abstract

Objective: This study aimed to assess survival outcomes in older patients with de novo metastatic prostate cancer who initially received androgen deprivation therapy. Methods: The retrospective multicenter study included 2784 men with metastatic prostate cancer who were treated with androgen deprivation therapy between 2008 and 2017. Patients were classified into <75, 75–79, and ≥80 age groups. Propensity score matching was conducted to assess the cancer‐specific survival of the groups. The 5‐year net overall survival of each group was derived to evaluate relative survival compared with the general population using the Pohar–Perme estimator and the 2019 Japan Life Table. Results: During the follow‐up (median, 34 months), 1014 patients died, of which 807 died from metastatic prostate cancer progression. Compared with the <75 group, the cancer‐specific survival of the 75–79 group was similar (hazard ratio 1.07; 95% confidence interval 0.84–1.37; P = 0.580), whereas that of the ≥80 group was significantly worse (hazard ratio 1.41; 95% confidence interval 1.10–1.80; P = 0.006). The 5‐year net overall survival of the <75, 75–79, and ≥80 age groups were 0.678, 0761, and 0.718, respectively. The 5‐year net overall survival of patients aged ≥80 years with low‐ and high‐volume disease were 0.893 and 0.586, respectively, which was comparable with those in patients aged <75 years (0.872 and 0.586, respectively). Conclusions: Older metastatic prostate cancer patients aged ≥80 years had poorer cancer‐specific survival compared with younger patients. Conversely, 5‐year net overall survival in older patients aged ≥80 years was comparable with that in younger patients aged <75 years. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

39. Genitourinary Toxicity After High-Dose-Rate (HDR) Brachytherapy Combined With Hypofractionated External Beam Radiotherapy for Localized Prostate Cancer: An Analysis to Determine the Correlation Between Dose–Volume Histogram Parameters in HDR Brachytherapy and Severity of Toxicity

Author

Ishiyama, Hiromichi, Kitano, Masashi, Satoh, Takefumi, Kotani, Shouko, Uemae, Mineko, Matsumoto, Kazumasa, Okusa, Hiroshi, Tabata, Ken-ichi, Baba, Shiro, and Hayakawa, Kazushige

Published
2009
Full Text
View/download PDF

43. Efficacy of combined androgen blockade therapy in patients with metastatic hormone‐sensitive prostate cancer stratified by tumor burden.

Author

Nagumo, Yoshiyuki, Onozawa, Mizuki, Kojima, Takahiro, Terada, Naoki, Shiota, Masaki, Mitsuzuka, Koji, Yasumoto, Hiroaki, Matsumoto, Hiroaki, Enokida, Hideki, Sugiyama, Takayuki, Kuroiwa, Kentaro, Saito, Toshihiro, Yokomizo, Akira, Kohei, Naoki, Tabata, Ken‐ichi, Takahashi, Atsushi, Sugimoto, Mikio, Kitamura, Hiroshi, Kamoto, Toshiyuki, and Nishiyama, Hiroyuki

Subjects
PROSTATE cancer, PROSTATE cancer prognosis, ANDROGEN deprivation therapy, PROGRESSION-free survival, ANDROGENS, PROSTATE cancer patients
Abstract

Objective: To determine the effect of combined androgen blockade with a first‐generation anti‐androgen on the prognoses of metastatic hormone‐sensitive prostate cancer patients stratified by tumor burden. Methods: We retrospectively analyzed the cases of metastatic hormone‐sensitive prostate cancer patients who were treated with androgen deprivation therapy in 2008–2017 at 30 institutions in Japan. To compare the overall survival and progression‐free survival rates of the patients treated with castration monotherapy and combined androgen blockade, we carried out a Cox proportional hazards regression analysis using both inverse probability of treatment weighting and instrumental variables methods. High‐burden disease was defined as the presence of four or more bone metastases and/or visceral metastasis. Results: Of 2048 patients, 702 (34.3%) and 1346 (65.7%) patients were classified as the low‐ and high‐burden groups, respectively. In each group, >80% of the patients were treated with combined androgen blockade. Although there was no significant between‐group difference in the overall survival according to the androgen deprivation therapy method, in the high‐burden group the progression‐free survival of the combined androgen blockade‐treated patients was significantly better than that of patients treated with castration monotherapy: inverse probability of treatment weighting method, hazard ratio 0.49, 95% confidence interval 0.34–0.71; instrumental variables method, hazard ratio 0.80, 95% confidence interval 0.60–0.98. Conclusion: In the high‐burden group, combined androgen blockade with a first‐generation anti‐androgen resulted in superior progression‐free survival compared with castration monotherapy. For well‐selected metastatic hormone‐sensitive prostate cancer patients, the use of combined androgen blockade might still have some suitable scenarios. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

44. 長期経過観察中膀胱尿管移行部再発性尿路上皮癌に対して, 尿管部分切除術・膀胱尿管新吻合術を施行した1例

Author

Shimura, Soichiro, Matsumoto, Kazumasa, Tabata, Ken-ichi, Fujita, Tetsuo, and Iwamura, Masatsugu

Subjects
Ureteroneocystostomy, Urothelial carcinoma, 494.9, urologic and male genital diseases, Partial ureterectomy, female genital diseases and pregnancy complications
Abstract

A 54-year-old woman who had been treated with transurethral resection of bladder tumor for nonmuscle invasive urothelial carcinoma approximately nine years before presented with gross hematuria. Cystoscopy demonstrated a papillary tumor at the left side of the ureteral orifice. Magnetic resonance imaging showed a 1.3 cm non-muscle invasive lesion in the lower ureter from the ureteral orifice. She suffered from connective tissue disease treated with steroids. To avoid renal failure, we performed partial ureterectomy and ureteroneocystostomy. Pathological findings revealed pT1 urothelial carcinoma with negative surgical margin. There have been no signs of recurrence during eight years of follow-up after the last treatment.

Published
2018

45. Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial

Author

Uemura, Hiroji, primary, Matsushima, Hisashi, additional, Kobayashi, Kazuki, additional, Mizusawa, Hiroya, additional, Nishimatsu, Hiroaki, additional, Fizazi, Karim, additional, Smith, Matthew, additional, Shore, Neal, additional, Tammela, Teuvo, additional, Tabata, Ken-ichi, additional, Matsubara, Nobuaki, additional, Iinuma, Masahiro, additional, Uemura, Hirotsugu, additional, Oya, Mototsugu, additional, Momma, Tetsuo, additional, Kawakita, Mutsushi, additional, Fukasawa, Satoshi, additional, Kobayashi, Tadahiro, additional, Kuss, Iris, additional, Le Berre, Marie-Aude, additional, Snapir, Amir, additional, Sarapohja, Toni, additional, and Suzuki, Kazuhiro, additional

Published
2020
Full Text
View/download PDF

49. Local and Distant Effects of Caveolin-1 on Prostate Cancer Progression

Author

Thompson, T. C., primary, Tahir, S. A., additional, Li, L., additional, Watanabe, M., additional, Naruishi, K., additional, Yang, G., additional, Tabata, Ken-ichi, additional, Kurosaka, S., additional, Edamura, K., additional, Tanimoto, R., additional, Corn, P., additional, Kadmon, D., additional, Logothetis, C. J., additional, Troncoso, P., additional, Ren, C., additional, Goltsov, A., additional, and Park, S., additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results